AOC Development: Conjugation Site Selection, DAR Control & In Vitro Testing | Full Webinar

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

Oligonucleotide therapeutics hold great promise, but extrahepatic delivery remains a challenge. Antibody–oligonucleotide conjugates (AOCs) are emerging as a powerful solution – provided you can master conjugation chemistry, DAR control, analytical characterization, and functional assessment. https://www.youtube.com/watch?v=CNr9ZsU2qrk In this recorded webinar, our experts from Medicilon cover: How conjugation chemistry impacts AOC consistency and developability Why DAR control […]

BioTrinity 2026

Meet Medicilon at BioTrinity 2026

April 14-15, 2026
Convene, 133 Houndsditch, London EC3A 7BX, United Kingdom

Search Medicilon

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

Medicilon and Protheragen Forge Strategic Partnership to Build a Collaborative “Project + Platform” Model

Medicilion Congratulates MediLink Therapeutics on Licensing B7H3 ADC to Roche

AOC Development: Conjugation Site Selection, DAR Control & In Vitro Testing | Full Webinar

Meet Medicilon at BioTrinity 2026

BioTrinity 2026

Contact Medicilon

Name(Required)
Address(Required)